{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:45:55Z","timestamp":1789580755691,"version":"build-2803163510"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6,6]]},"abstract":"<jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>Pancreatic neuroendocrine carcinoma (PNEC) is a rare, aggressive malignancy with limited therapeutic options and a dismal prognosis, particularly in young patients. Approximately 85% of PNEC cases eventually progress to metastatic cancer. Despite advances in oncology, optimal management strategies for metastatic PNEC remain undefined, especially in chemotherapy-ineligible cases.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>An 18-year-old male patient, reporting anorexia with associated weight loss (15\u2009kg weight loss over 3 months) and significant abdominal distension.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnoses:<\/jats:title>\n            <jats:p>The results of whole abdominal computed tomography, histopathology, immunohistochemistry, and laboratory examination were consistent with pancreatic neuroendocrine carcinoma with liver metastasis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>Due to the family refusal of chemotherapy, and immunohistochemistry revealed programmed death-1 ligand positivity. The patient received penpulimab (anti-programmed death-1) combined with anlotinib capsules and then changed to penpulimab combined with sorafenib capsules after progression.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>Initial therapy achieved 13 months of progression-free survival, demonstrating durable disease control. Subsequent progression highlighted challenges of acquired resistance, with no severe treatment-related toxicity. The patient was still alive at the time of follow-up in July 2024.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>Pancreatic neuroendocrine cancer is rare. There are various treatment options available. However, the best treatment plan still needs further exploration. This case underscores that programmed death-1 ligand\u2005+\u2005PNEC may respond to immunotherapy\/antiangiogenic combinations, offering alternatives for chemotherapy-ineligible patients. In addition, young patients with aggressive PNEC represent an understudied population, necessitating tailored strategies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000042730","type":"journal-article","created":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T21:02:41Z","timestamp":1749502961000},"page":"e42730","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Penpulimab in an adolescent patient with pancreatic neuroendocrine carcinoma with liver metastasis: A case report and literature review"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7463-8021","authenticated-orcid":false,"given":"Yafen","family":"Li","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, Wanbei Coal and Electricity Group General Hospital, Suzhou, Anhui, China"},{"name":"General Clinical Research Center, Wanbei Coal and Electricity Group General Hospital, Suzhou, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Wanbei Coal and Electricity Group General Hospital, Suzhou, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Wanbei Coal and Electricity Group General Hospital, Suzhou, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy, Wanbei Coal and Electricity Group General Hospital, Suzhou, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Oncology, Wanbei Coal and Electricity Group General Hospital, Suzhou, Anhui, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyu","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy, Wanbei Coal and Electricity Group General Hospital, Suzhou, Anhui, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250609","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.3390\/diagnostics13132154","article-title":"Somatostatin receptor targeted PET-CT and its role in the management and theranostics of gastroenteropancreatic neuroendocrine neoplasms.","volume":"13","author":"Adnan","year":"2023","journal-title":"Diagnostics (Basel)"},{"key":"R2-20250609","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1177\/08465371241239037","article-title":"Cinematic rendering of pancreatic neuroendocrine tumours: opportunities for clinical implementation: part 1: tumour detection and characterization.","volume":"75","author":"Ahmed","year":"2024","journal-title":"Can Assoc Radiol J"},{"key":"R3-20250609","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.suc.2008.10.001","article-title":"The surgical and systemic management of neuroendocrine tumors of the pancreas.","volume":"89","author":"Abood","year":"2009","journal-title":"Surg Clin North Am"},{"key":"R4-20250609","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1159\/000443171","article-title":"ENETS consensus guidelines update for the management of patients with functional pancreatic neuroendocrine tumors and non-functional pancreatic neuroendocrine tumors.","volume":"103","author":"Falconi","year":"2016","journal-title":"Neuroendocrinology"},{"key":"R5-20250609","doi-asserted-by":"crossref","first-page":"4301","DOI":"10.3390\/jcm12134301","article-title":"Review of the immune checkpoint inhibitors in the context of cancer treatment.","volume":"12","author":"Alturki","year":"2023","journal-title":"J Clin Med"},{"key":"R6-20250609","doi-asserted-by":"crossref","first-page":"106221","DOI":"10.1016\/j.intimp.2020.106221","article-title":"CTLA-4: from mechanism to autoimmune therapy.","volume":"80","author":"Hosseini","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"R7-20250609","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12943-021-01489-2","article-title":"Combination strategies with PD-1\/PD-L1 blockade: current advances and future directions.","volume":"21","author":"Yi","year":"2022","journal-title":"Mol Cancer"},{"key":"R8-20250609","doi-asserted-by":"crossref","first-page":"e12943","DOI":"10.1111\/jne.12943","article-title":"Role of immunotherapy in gastro-enteropancreatic neuroendocrine neoplasms (GEP-NENs): current advances and future directions.","volume":"33","author":"Fang","year":"2021","journal-title":"J Neuroendocrinol"},{"key":"R9-20250609","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1007\/s11154-021-09647-z","article-title":"Present and future of immunotherapy in neuroendocrine tumors.","volume":"22","author":"Albertelli","year":"2021","journal-title":"Rev Endocr Metab Disord"},{"key":"R10-20250609","doi-asserted-by":"crossref","first-page":"e3004","DOI":"10.1038\/cddis.2017.401","article-title":"Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.","volume":"8","author":"Cavalcanti","year":"2017","journal-title":"Cell Death Dis"},{"key":"R11-20250609","doi-asserted-by":"crossref","first-page":"484","DOI":"10.7150\/jca.13711","article-title":"The impact of PD-L1 expression in patients with metastatic GEP-NETs.","volume":"7","author":"Kim","year":"2016","journal-title":"J Cancer"},{"key":"R12-20250609","doi-asserted-by":"crossref","first-page":"3021","DOI":"10.1002\/cncr.32883","article-title":"Pembrolizumab for the treatment of programmed death-ligand 1-positive advanced carcinoid or pancreatic neuroendocrine tumors: results from the KEYNOTE-028 study.","volume":"126","author":"Mehnert","year":"2020","journal-title":"Cancer"},{"key":"R13-20250609","doi-asserted-by":"crossref","first-page":"8801","DOI":"10.18632\/oncotarget.23753","article-title":"Immune checkpoint inhibitors in neuroendocrine tumors: a single institution experience with review of literature.","volume":"9","author":"Chauhan","year":"2017","journal-title":"Oncotarget"},{"key":"R14-20250609","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1007\/s40265-021-01640-9","article-title":"Penpulimab: first approval.","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"R15-20250609","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s13045-016-0332-8","article-title":"Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors.","volume":"9","author":"Sun","year":"2016","journal-title":"J Hematol Oncol"},{"key":"R16-20250609","first-page":"578","article-title":"A case of pancreatic cancer treated with chemotherapy combined with immunotherapy and targeted therapy.","volume":"52","author":"Zhang","year":"2023","journal-title":"Zhejiang Da Xue Xue Bao Yi Xue Ban"},{"key":"R17-20250609","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0140-6736(16)00141-0","article-title":"Pancreatic cancer.","volume":"388","author":"Kamisawa","year":"2016","journal-title":"Lancet"},{"key":"R18-20250609","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.path.2019.08.007","article-title":"Neuroendocrine tumors of the gastrointestinal tract and pancreas.","volume":"12","author":"Patel","year":"2019","journal-title":"Surg Pathol Clin"},{"key":"R19-20250609","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s11912-022-01217-z","article-title":"Neuroendocrine tumors: a relevant clinical update.","volume":"24","author":"Rizen","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"R20-20250609","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/BF02067341","article-title":"Clinical characteristics, treatment and survival in patients with pancreatic tumors causing hormonal syndromes.","volume":"16","author":"Grama","year":"1992","journal-title":"World J Surg"},{"key":"R21-20250609","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/S1072-7515(00)00222-2","article-title":"Hepatic neuroendocrine metastases: does intervention alter outcomes?","volume":"190","author":"Chamberlain","year":"2000","journal-title":"J Am Coll Surg"},{"key":"R22-20250609","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/SLA.0000000000000348","article-title":"Regional lymphadenectomy is indicated in the surgical treatment of pancreatic neuroendocrine tumors (PNETs).","volume":"259","author":"Hashim","year":"2014","journal-title":"Ann Surg"},{"key":"R23-20250609","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11523-012-0229-6","article-title":"Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.","volume":"7","author":"Tijeras-Raballand","year":"2012","journal-title":"Target Oncol"},{"key":"R24-20250609","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N Engl J Med"},{"key":"R25-20250609","doi-asserted-by":"crossref","first-page":"5071","DOI":"10.1245\/s10434-023-13383-w","article-title":"Sintilimab plus modified FOLFIRINOX in metastatic or recurrent pancreatic cancer: the randomized phase II CISPD3 trial.","volume":"30","author":"Fu","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"R26-20250609","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1002\/cncr.33591","article-title":"A phase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART) SWOG S1609: high-grade neuroendocrine neoplasm cohort.","volume":"127","author":"Patel","year":"2021","journal-title":"Cancer"},{"key":"R27-20250609","doi-asserted-by":"crossref","first-page":"4454","DOI":"10.1158\/1078-0432.CCR-20-0621","article-title":"Immunotherapy of ipilimumab and nivolumab in patients with advanced neuroendocrine tumors: a subgroup analysis of the CA209\u2013538 clinical trials for rare cancers.","volume":"26","author":"Klein","year":"2020","journal-title":"Clin Cancer Res"},{"key":"R28-20250609","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1038\/s41467-023-38611-5","article-title":"Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin.","volume":"14","author":"Capdevila","year":"2023","journal-title":"Nat Commun"},{"key":"R29-20250609","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/s41392-024-01857-6","article-title":"First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel\/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial.","volume":"9","author":"Sha","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R30-20250609","doi-asserted-by":"crossref","first-page":"e009034","DOI":"10.1136\/jitc-2024-009034","article-title":"Fc-Fc interactions and immune inhibitory effects of IgG4: implications for anti-PD-1 immunotherapies.","volume":"12","author":"Zhang","year":"2024","journal-title":"J ImmunoTher Cancer"},{"key":"R31-20250609","doi-asserted-by":"crossref","first-page":"924542","DOI":"10.3389\/fimmu.2022.924542","article-title":"Penpulimab, an Fc-engineered IgG1 anti-PD-1 antibody, with improved efficacy and low incidence of immune-related adverse events.","volume":"13","author":"Huang","year":"2022","journal-title":"Front Immunol"},{"key":"R32-20250609","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/nrclinonc.2018.9","article-title":"Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa.","volume":"15","author":"Khan","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R33-20250609","doi-asserted-by":"crossref","first-page":"1110624","DOI":"10.3389\/fendo.2023.1110624","article-title":"A real-world study of anlotinib combined with GS regimen as first-line treatment for advanced pancreatic cancer.","volume":"14","author":"Zhan","year":"2023","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042730","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,9]],"date-time":"2025-06-09T21:02:46Z","timestamp":1749502966000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000042730"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":33,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000042730","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]}}}